Efficacy and gene expression results from SOLTI1007, a phase II study evaluating neoadjuvant eribulin in hormone receptor (HR)-positive/HER2-negative breast cancer

Wuerstlein, R.; Prat, A.; Ortega,; Pare, L.; Galvan, P.; Nuciforo, P.; Oliverira, M.; Amillano, K.; Lopez, R.; Lluch, A.; Morales, S.; Gonzales, R.; Manso, L.; Martinez, J.; Llombart, A.; de la Pena, L.; di Cosimo, S.; Rubio, I.; Baselga, J.; Cortes, J.; Harbeck, N.

Links

ORCID

Tools

Export citation

Search in Google Scholar

Efficacy and gene expression results from SOLTI1007, a phase II study evaluating neoadjuvant eribulin in hormone receptor (HR)-positive/HER2-negative breast cancer

Journal article published in 2016 by R. Wuerstlein, A. Prat, Ortega, L. Pare, P. Galvan, P. Nuciforo, M. Oliverira, K. Amillano, R. Lopez, A. Lluch, S. Morales

, R. Gonzales, L. Manso, J. Martinez, A. Llombart and other authors.

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Preprint: policy unknown

Upload

Postprint: policy unknown

Upload

Published version: policy unknown

Upload